A First-in-Human (FIH), Randomized, Dose-Escalation, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPC5001 Administered to Healthy Subjects and Subjects With Familial Hypercholesterolemia (FH)
Phase of Trial: Phase I
Latest Information Update: 25 Apr 2014
At a glance
- Drugs SPC 5001 (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions
- Sponsors Santaris Pharma
- 04 Oct 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 18 May 2011 Actual initiation date changed from Apr 2011 to May 2011 as reported by ClinicalTrials.gov.
- 09 May 2011 Planned end date (Nov 2011) added as reported by ClinicalTrials.gov.